Belgium biotech company translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, Agomab is building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.
Agomab’s pipeline consists of its lead candidate AGMB-129, a gastrointestinal tract restricted ALK-5 inhibitor for the treatment of fibrostenotic Crohn’s disease that is currently being investigated in a Phase 1 clinical trial in healthy volunteers. The second TGF-ß-targeting drug candidate, AGMB-447, is a lung-restricted ALK-5-inhibitor in development for treatment of idiopathic pulmonary fibrosis. AGMB-101 is a full agonist against the MET receptor in development for the treatment of organ failure. Both of these preclinical candidates, AGMB-447 and AGMB-101, are currently in IND-enabling studies. Additionally, Agomab recently expanded its research pipeline with a partial MET-receptor agonist, AGMB-102, for a range of fibrotic indications.
Agomab’s pipeline consists of its lead candidate AGMB-129, a gastrointestinal tract restricted ALK-5 inhibitor for the treatment of fibrostenotic Crohn’s disease that is currently being investigated in a Phase 1 clinical trial in healthy volunteers. The second TGF-ß-targeting drug candidate, AGMB-447, is a lung-restricted ALK-5-inhibitor in development for treatment of idiopathic pulmonary fibrosis. AGMB-101 is a full agonist against the MET receptor in development for the treatment of organ failure. Both of these preclinical candidates, AGMB-447 and AGMB-101, are currently in IND-enabling studies. Additionally, Agomab recently expanded its research pipeline with a partial MET-receptor agonist, AGMB-102, for a range of fibrotic indications.
Location: Belgium, East Flanders, Ghent
Employees: 11-50
Total raised: $401.25M
Founded date: 2017
Investors 5
| Date | Name | Website |
| - | V-Bio Vent... | v-bio.vent... |
| 21.07.2022 | Asabys Par... | asabys.com... |
| - | Andera Par... | anderapart... |
| - | Omnes Capi... | omnescapit... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 28.10.2024 | Series D | $89M | - |
| 13.10.2023 | Series C | $100.63M | - |
| 13.07.2022 | Series B | $114M | Asabys Par... |
| 10.03.2021 | Series B | $74M | V-Bio Vent... |
| 03.04.2019 | Series A | $23.61M | - |
Mentions in press and media 26
| Date | Title | Description |
| 09.02.2026 | Agomab, portfolio company of Andera Partners, completes successful Nasdaq listing with $200 million IPO | Andera Partners announced today that Agomab, one of its portfolio companies, has completed a $200 million initial public offering on the NASDAQ stock market. The Company is trading under the ticker AGMB and it made its public market debut o... |
| 22.05.2025 | Belgium’s bold tech revolution at the heart of Europe | Belgium's tech ecosystem is showing strong signs of growth, maturation, and increasing global relevance. According to European Tech 2024: The Big Picture, Belgian tech companies raised over €4.2 billion in 2024. Major deals included funding... |
| 11.11.2024 | October 2024's top 10 European tech deals you need to know about | According to the Tech.eu database, European tech companies raised €4 billion over the course of October 2024. This figure is nearly the same as last month when European tech companies raised €4.2 billion in September. Compared to October 20... |
| 28.10.2024 | Agomab's $89 Million Boost: A Leap Towards Fibrosis Solutions | Agomab Therapeutics is on the rise. The Belgium-based biotech company recently secured $89 million in a Series D funding round. This infusion of capital comes from a mix of new and existing investors, including heavyweights like Sanofi and ... |
| 28.10.2024 | Agomab: $89 Million (Series D) Raised For Supporting Broad Fibrosis-Focused Pipeline | Agomab Therapeutics announced a $89 million (€82.1 million) Series D funding round, with participation from new investors Sanofi and Invus, as well as existing investors. The proceeds from this Series D funding round will be used to further... |
| 25.10.2024 | Yoga Joint Raises $12M in Funding | Yoga Joint, a Boca Raton, FL-based chain of hot yoga and fitness studios, raised $12M in funding for its Joint Venture program. Backers were not disclosed. The company intends to use the funds to continue its expansion, opening locations in... |
| 25.10.2024 | Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis-focused Pipeline | Agomab Therapeutics NV (‘Agomab’) today announced a $89 million (€82.1 million) Series D financing round, with participation from new investors Sanofi and Invus, as well as existing investors. The proceeds from the Series D will be used to ... |
| 25.10.2024 | Agomab Raises $89M in Series D Financing | Agomab Therapeutics, an Antwerp, Belgium-based biotech company developing novel treatments that aim to preserve and restore organ function in fibrotic diseases, raised $89M in Series D funding. Backers included Sanofi and Invus. Led by CEO ... |
| 13.06.2024 | Belgium: Nurturing tech talent and entrepreneurship in the heart of Europe | Strategically located in the heart of Europe, Belgium leverages its multilingual and highly educated workforce to foster innovation and entrepreneurship. The nation's tech scene boasts a robust mix of startups, scale-ups, and established co... |
| 13.10.2023 | Agomab Therapeutics secures €94.9M in Series C to advance drug development for Crohn's Disease | This week, Belgium medtech company Agomab Therapeutics announced the closing of a €94.9 million Series C financing round led by Fidelity Management & Research Company. The company is pioneering and developing novel treatments using grow... |
Show more